Celltrion Aims to Market 11 Biosimilars in Japan, Infliximab “Biobetter” in the List

October 3, 2022
Celltrion Japan President Houng Kim Celltrion Healthcare is expanding its pipeline of biosimilars in Japan. Of its six products approved globally, two are already on the market and four more are coming along well in development. With a further five...read more